NH

Future of B2B Payments Starts with Automation and Efficiency, Finds New Bottomline, Strategic Treasurer Survey

Retrieved on: 
Tuesday, October 5, 2021
AP, Adoption, Compliance, Efficiency, Solution, Partner, ACH, NASDAQ, Ownership, Partnership, RTP, Product management, Growth, Risk management, Technology, Fraud, Blockchain, Automation, Investment, GLOBE, Online shopping, Cryptocurrency

This is being driven by demand from corporate customers who are seeking system integrations and embedded payments experiences.

Key Points: 
  • This is being driven by demand from corporate customers who are seeking system integrations and embedded payments experiences.
  • The survey also identified a trend toward single payments solutions, with half of banks saying their clients prefer this and 65% of corporates reporting a preference toward single solutions.
  • Efficiency continues to be the top driver for payments solutions with 47% of respondents reporting efficiency as the reason to evaluate and implement new payments automation solutions.
  • While we are continuing to see greater adoption of electronic B2B payments, more work needs to be done, said Craig Jeffery, founder and managing partner of Strategic Treasurer.

ERI partners with Bottomline to extend financial messaging solutions to financial institutions

Retrieved on: 
Tuesday, October 5, 2021
Software as a service, Software, Business development, Partnership, NASDAQ, ERI, Data management, Maintenance, COO, GLOBE, Cryptocurrency, Online shopping

Its SaaS offering is a comprehensive portfolio of products for financial messaging, reconciliation, business flow integration, market data and other services related to the payments and securities business.

Key Points: 
  • Its SaaS offering is a comprehensive portfolio of products for financial messaging, reconciliation, business flow integration, market data and other services related to the payments and securities business.
  • Jean-Philippe Bersier, ERIs Director of Business Development, says: ERI has a long collaboration history with Bottomline, and a significant number of our clients use Bottomline solutions daily with great satisfaction.
  • Operating in many of the major financial centres, ERI is present in Geneva, Zurich, Lugano, London, Luxembourg, Singapore and Paris.
  • More than 400 banks and financial institutions across 60 countries in Europe, the Middle East, Africa, the Americas and Asia have already chosen the OLYMPIC Banking System.

NhTherAguix: NH THERAGUIX announces the enrolment in Boston of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancrea

Retrieved on: 
Friday, October 1, 2021
Phase II, University of Lyon, Neoplasm, DRS, Radiation, Diagnosis, Pancreatic cancer, Patient, Recurrence, Brain, Regulatory News Service, NH, Phases of clinical research, Method, CEO, Medicine, University, ILM, Technology, NIH, NHT, Survival, Nanoparticle, Safety, Nanomedicine, Quality of life, Pharmaceutical industry, Medical imaging, AGUIX(R), NH THERAGUIX

NANOBRAINMETS is a double-blind, placebo-controlled randomized Phase II clinical trial of stereotactic radiation with or without AGuIX(R) gadolinium-based nanoparticles in the management of brain metastases at higher-risk of local recurrence with radiation alone.

Key Points: 
  • NANOBRAINMETS is a double-blind, placebo-controlled randomized Phase II clinical trial of stereotactic radiation with or without AGuIX(R) gadolinium-based nanoparticles in the management of brain metastases at higher-risk of local recurrence with radiation alone.
  • This study follows the results already obtained by NH TherAguix through the NANORAD Phase I trial that demonstrated very promising results [1] .
  • Dr. Ayal Aizer stated, "Increasingly, the mainstay of management for patients with brain metastases involves brain-directed stereotactic radiation.
  • AGuIX(R) is currently also being tested through another Phase II trial in brain metastasis, using whole brain radiation therapy (NANORAD 2).

iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography

Retrieved on: 
Wednesday, September 29, 2021

NASHUA, N.H., Sept. 29, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI® Risk for digital breast tomosynthesis (DBT), or 3D mammography, as well as an updated version of PowerLook® Density Assessment. Both technologies offer improved accuracy and enhanced functionality compared to previous versions of the software.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI Risk for digital breast tomosynthesis (DBT), or 3D mammography, as well as an updated version of PowerLook Density Assessment.
  • The latest generation of ProFound AI Risk offers the ability to calculate a short-term risk estimation for 3D mammography, with greater accuracy compared to both the previous version of the risk software based on 2D mammography and traditionally used risk models.
  • The latest version of ProFound AI Risk offers expanded features, including:
    The ability to calculate short-term (one-, two- or three-year) absolute risk based on either 2D or 3D mammography images.
  • Results include the womans absolute breast cancer risk score and breast cancer risk category [low, general, moderate and high].

NhTherAguix: NH TherAguix announces the launch of its IPO on the Euronext Growth market in Paris

Retrieved on: 
Tuesday, September 28, 2021
ISIN, ODD, Glioblastoma, Harvard University, Cancer, Omnes, Partnership, Exercise, Hope, Dana–Farber Cancer Institute, Observation, MRI, Pancreatic cancer, Risk, Radiosurgery, A Translation Guide to 19th-Century Polish-Language Civil-Registration Documents, Brain, Regulatory News Service, Pea, Patient, NH, Article, AMF, Toxicity, Magnetic resonance imaging, Company, Prospectus, Growth, Technology, IPO, Human, Bpifrance, Research, Tissue, Chapter Three, Radiation, Sanofi, Nanomedicine, Nanoparticle, Safety, Survival, Risk factor, EPR, Euronext Growth, Neoplasm, Security (finance), Medical device, Medical imaging, Pharmaceutical industry

To do this, we have developed AGuIX(R) so that it can be integrated into all current care protocols, without changing patient treatment.

Key Points: 
  • To do this, we have developed AGuIX(R) so that it can be integrated into all current care protocols, without changing patient treatment.
  • I hope I can count on the support of many institutional and retail investors in this human and entrepreneurial adventure."
  • Based on this observation, NH TherAguix has developed an innovative theranostic [1] approach in nanomedicine: AGuIX(R).
  • Approval of the Prospectus should not be considered as a favourable opinion on the securities offered or admitted for trading on the Euronext Growth market in Paris.

Position Imaging Launches “Intelligent Logistics” Podcast Series

Retrieved on: 
Wednesday, September 22, 2021
E-commerce, Podcasts (software), Population, From Negative Stereotype to Positive Image, CEO, Confusion, Technology, COVID-19, Research, Organization, Industry, GLOBE, Warehouse, Retail

STRATHAM, N.H., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Position Imaging, Inc , a pioneer in omnichannel logistics fulfillment and asset tracking, today announced the company has launched a new podcast series titled Intelligent Logistics, now available on Apple Podcasts and Spotify .

Key Points: 
  • STRATHAM, N.H., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Position Imaging, Inc , a pioneer in omnichannel logistics fulfillment and asset tracking, today announced the company has launched a new podcast series titled Intelligent Logistics, now available on Apple Podcasts and Spotify .
  • Position Imagings podcast series will take a vendor-agnostic dive into rapidly evolving technology, customer expectations, and trends to address questions such as:
    What are intelligent logistics, and how can organizations implement this advanced strategy for keeping pace with a rapidly advancing world?
  • Our podcast will look into many examples of intelligent logistics impacting the way our society moves goods.
  • Position Imaging is a technology company focused on innovations to improve the logistics industry.

Position Imaging Expands Executive Team To Support Engineering, Sales, And Service

Retrieved on: 
Wednesday, September 15, 2021
Online, Haynes, Microsoft, Software as a service, Kurt Knoff, From Negative Stereotype to Positive Image, CEO, AT&T, AAA, Apple, Software, AT, Safety, Industry, COO, Machine learning, Solution, Growth, Sillman, Senior, Tile, Parcel, Maintenance, OnLive, GLOBE, Google, E-commerce, Management, Online shopping

The new appointments underscore Position Imagings strong growth and need for additional resources to oversee its rapidly expanding retail and residential sales.

Key Points: 
  • The new appointments underscore Position Imagings strong growth and need for additional resources to oversee its rapidly expanding retail and residential sales.
  • Customers, both residential and retail, are seeking an easy, contact-free, self-serve experience when retrieving packages, purchases or conducting returns, said Ned Hill, Founder, and CEO, Position Imaging.
  • Dick Sillman joins Position Imaging as Vice President of Engineering and brings extensive experience delivering many products in the enterprise, industrial, and consumer electronics domains.
  • Matt Haynes brings twenty years of multifamily experience to Position Imaging and joins as senior vice president of sales.

NH TherAguix registration document approved by Autorité des Marchés Financiers as part of planned IPO on Euronext Growth Paris

Retrieved on: 
Monday, September 13, 2021

NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the approval of its registration document by the Autorit des marchs financiers (the "AMF") under number I.21-048 dated 10 September 2021.

Key Points: 
  • NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the approval of its registration document by the Autorit des marchs financiers (the "AMF") under number I.21-048 dated 10 September 2021.
  • The approval of the document marks the first step in the planned NH TherAguix IPO on the Euronext Growth market in Paris, which remains subject to favourable market conditions and AMF approval of the relevant prospectus.
  • Based on this observation, NH TherAguix has developed an innovative theranostic [1] approach in nanomedicine: AGuIX(R).
  • The registration document contains a detailed description of NH TherAguix, including its business activity, strategy and financial position, as well as the corresponding risk factors.

iCAD to Host Educational Roundtable to Help Clinicians and Facilities Recover from COVID-19 Impact

Retrieved on: 
Thursday, September 9, 2021

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host an educational roundtable event to help clinicians and their facilities recover from the impact of the COVID-19 pandemic.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host an educational roundtable event to help clinicians and their facilities recover from the impact of the COVID-19 pandemic.
  • Clinicians are in need of new solutions to navigate todays challenges, said Stacey Stevens, President of iCAD.
  • This educational roundtable features leading experts who will discuss their experiences with pandemic-related clinical, economic and volume-based challenges, as well as best practices on leveraging new technologysuch as ProFound AIto help overcome these hurdles.
  • iCAD is proud to be an integral partner in helping providers and facilities recover from the impact of the COVID-19 pandemic and provide the highest quality care to patients.

Unitil Announces Exercise and Closing of Option by Underwriters

Retrieved on: 
Wednesday, September 8, 2021

Unitil Corporation provides energy for life by safely and reliably delivering natural gas and electricity in New England.

Key Points: 
  • Unitil Corporation provides energy for life by safely and reliably delivering natural gas and electricity in New England.
  • We are committed to the communities we serve and to developing people, business practices, and technologies that lead to the delivery of dependable, more efficient energy.
  • Unitil Corporation is a public utility holding company with operations in Maine, New Hampshire and Massachusetts.
  • Unitil undertakes no obligation, and does not intend, to update these forward-looking statements, except as required by law.